A phase 3, multi-center, observer blind, controlled, randomized study to compare the immunogenicity and safety of the concomitant administration of a combined tetanus, reduced diphtheria, and acellular pertussis (Tdap) vaccine and Chiron meningococcal ACWY conjugate vaccine, with either one dose of acellular pertussis (Tdap) vaccine, or one dose of Chiron meningococcal ACWY conjugate vaccine, in healthy subjects aged 11-25 years.

Trial Profile

A phase 3, multi-center, observer blind, controlled, randomized study to compare the immunogenicity and safety of the concomitant administration of a combined tetanus, reduced diphtheria, and acellular pertussis (Tdap) vaccine and Chiron meningococcal ACWY conjugate vaccine, with either one dose of acellular pertussis (Tdap) vaccine, or one dose of Chiron meningococcal ACWY conjugate vaccine, in healthy subjects aged 11-25 years.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2014

At a glance

  • Drugs DTaP vaccine (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Diphtheria; Meningococcal infections; Pertussis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors Chiron Corporation; Novartis
  • Most Recent Events

    • 28 Apr 2008 Interim results will be reported at PAS 2008, according to a Novartis media release.
    • 31 Jan 2008 Status changed from in progress to completed according to ClinicalTrials.gov
    • 05 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top